Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon

Peripheral Arterial Disease Clinical Trial

— SWING  

Official title:

A Prospective, Multi-Center, Single-Arm, Feasibility Study to Assess the Safety and Performance WIth the SUNDANCE™ DruG Coated Balloon for the Treatment of De Novo or Restenotic Lesions in Infra-Popliteal Arteries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04107298
• Other study ID #: SUR19-002
• Status: Completed
• Phase: N/A
• Start date: June 29, 2020
• Est. completion date: January 30, 2024

Study information

• Verified date: February 2024
• Source: SurModics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.

Description:

SWING is a prospective, multi-center, single-arm, feasibility study to assess the safety and performance of the Sundance™ drug coated balloon for the treatment of de novo or restenotic lesions in infra-popliteal Arteries. Approximately 35 subjects will be treated at up to 8 sites.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: January 30, 2024
• Est. primary completion date: August 23, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Clinical Inclusion Criteria

• Subject is =18 years.
• Subject has target limb Rutherford classification 4 or 5. Rutherford classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (i.e., no more than 7 Rutherford class 3 subjects may be enrolled in the study).
• Subject has provided written informed consent and is willing to comply with study follow-up requirements. Clinical Exclusion Criteria
• Subject has acute limb ischemia.
• Subject underwent intervention involving the target vessel (not a proximal inflow vessel) within the previous 90 days.
• Subject previously underwent PTA of the target lesion vessel using a DCB or DES.
• Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure.
• Subjects with heel gangrene, deep heel ulcers, osteomyelitis of tarsal or metatarsal bones (which extends beyond the metatarsal head immediately adjacent to the metatarso-phalangeal joint), and subjects with exposed vital structures (e.g., medial or lateral malleolus).
• Subjects requiring pedal angioplasty.
• Subjects that are non-ambulatory and confined to bed.
• Women who are pregnant, breast-feeding or intend to become pregnant or men who intend to father children during the time of the study.
• Subject has history of Class 3 (and above) congestive heart failure (CHF) in past 6 months.
• Subject has life expectancy less than 12 months.
• Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
• Subject has known hypersensitivity to sirolimus
• Subject has a known contraindication to the intended concomitant medications.
• Subject is allergic to ALL antiplatelet treatments.
• Subject has impaired renal function (i.e. serum creatinine level =2.5 mg/dL or =221 µmol/L).
• Subject had major limb amputation on the affected side in last year or has planned major limb amputation.
• Subject is receiving immunosuppressant therapy.
• Subject has known or suspected active infection at the time of the index procedure.
• Subject has platelet count <100,000/mm3 or >700,000/mm3.
• Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure.
• Subject is diagnosed with coagulopathy or other disorders which are contraindications for treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
• Subject has history of stroke within the past 3 months.
• Subject has a history of myocardial infarction within the past 30 days.
• Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
• Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol.
• Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
• Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure.
• Subject had previous bypass surgery of the target lesion.
• Subject had previously implanted stent in target lesion.
• Subject had previous treatment of the target vessel with thrombolysis or surgery.
• Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol. Angiographic Inclusion Criteria
• The target lesion/vessel must meet all of the following angiographic criteria for the

subject to participate in the trial:

• De novo lesion(s) or non-stented restenotic lesion
• Target lesion location starts at the P3 segment and terminates at 1cm above the ankle. Note: Isolated P3 lesion is not allowed. If a lesion starts in the P3 segment, it must continue into the infrapopliteal.
• Target vessel diameter =2 mm and =4 mm, based on visual estimation.
• Target lesion must have angiographic evidence of =70% stenosis by operator visual estimate.
• Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion. Use of re-entry/crossing devices is not allowed. Crossing may be performed retrograde, but treatment must be performed antegrade. Uncomplicated: Upon visual inspection, no occurrence of embolization, perforation, or occurrence of flow-limiting dissection.
• Target lesion(s) must be =230 mm in total lesion(s) length by operator visual estimate. A maximum of two lesions may be treated. The two lesions may be in one infrapopliteal vessel or in two distinct infrapopliteal vessels. Note: Tandem lesions may be considered a single lesion if they are separated by =30 mm.
• After pre-dilatation, the target lesion has =70% residual stenosis, absence of a flow limiting dissection (Grade D or greater) and treatable with available device matrix.
• A patent inflow artery free from significant stenosis (=50% stenosis) as confirmed by angiography.
• At least one patent native outflow artery to the ankle or foot distal to the lesion being treated, free from significant stenosis (=50% stenosis) as confirmed by angiography. Angiographic Exclusion Criteria
• Aneurysm in the target vessel or proximal inflow artery.
• Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length =15 cm.
• Significant stenosis (= 50%) in inflow lesion or occlusion in the ipsilateral iliac, SFA, popliteal arteries left untreated.
• Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, or re-entry devices.
• Significant target vessel tortuosity or other parameters prohibiting access to the target lesion.
• Presence of thrombus in the target vessel.

Related Conditions & MeSH terms

• Critical Lower Limb Ischemia
• Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• SUNDANCE™ Drug Coated Balloon
Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter

Locations

Country	Name	City	State
Australia	Royal Perth Hospital	Perth
Australia	Prince of Wales Private Hospital	Randwick
Australia	Royal North Shore Hospital	St Leonards
Austria	Universitäts Klinikum Graz	Graz
Germany	Universitäts-Herzzentrum Freiburg Bad Krozingen	Bad Krozingen
Germany	MEDINOS Kliniken des Landkreises Sonneberg GmbH	Sonneberg
Latvia	Paul Stradins University Hospital	Riga
New Zealand	Auckland City Hospital	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
SurModics, Inc.

Countries where clinical trial is conducted

Australia,  Austria,  Germany,  Latvia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death	MALE is defined as the composite of either major amputation or major re-intervention through 30 days of the index procedure. Major amputation is defined as limb amputation above the ankle. Major re-intervention is defined as the creation of new surgical bypass graft, the use of thrombectomy or thrombolysis, or major surgical graft revision such as a jump graft or an interposition graft.	30 Days
Primary	Primary Efficacy Endpoint: Rate of Late Lumen Loss (LLL)	LLL is assessed by quantitative vascular angiography (QVA). LLL is the difference between minimum lumen diameter (MLD) immediately after PTA and MLD at 6 months follow-up.	6 Months
Secondary	Rate of Device Success	Successful delivery, balloon inflation, deflation and retrieval of the intact study device	Acute/Periprocedural
Secondary	Rate of Technical Success	Successful vascular access, completion of endovascular procedure and immediate achievement of = 50% residual stenosis (by core lab-assessed quantitative vascular angiography) of the treated lesion on completion of angiography.	Acute/Periprocedural
Secondary	Rate of Procedure Success	Device Success or Technical Success and the absence of procedural complications.	Acute/Periprocedural
Secondary	Rate of Restenosis	Assessed by Transverse-view vessel area loss percentage (TVAL%) assessed by QVA. TVAL% of the target lesion at 6 months or prior to any clinically driven target lesion revascularization (CD-TLR) of the target lesion prior to 6 months.	6 Months or prior
Secondary	Number of Participants with Primary Patency	Freedom from target vessel occlusion as determined by DUS and CD-TLR. CD-TLR is defined as any TLR of the target lesion associated with deterioration of Rutherford Class and/or increase in size of pre-existing wounds and/or occurrence of new wound(s), and lesion restenosis >50% determined by angiography.	30 Days, 6 Months, 12 Months, 24 Months
Secondary	Major Adverse Event (MAE) rate	Composite rate of all-cause death, target limb major amputation and CD-TLR.	30 Days, 6 Months, 12 Months, 24 Months
Secondary	Amputation Free Survival	Rate of subjects not requiring major amputations	6 Months, 12 Months, 24 Months
Secondary	Hemodynamic outcomes	Change in ankle brachial index (ABI) and toe pressure from pre-procedure.	30 Days, 6 Months, 12 Months, 24 Months
Secondary	Change in Rutherford-Becker Classification	Change from pre-procedure	30 Days, 6 Months, 12 Months, 24 Months
Secondary	EQ-5D	The EQ-5D is not an abbreviation. It is a quality of Life evaluation quantified as the change from pre-procedure to time points specified below. The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.; The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'	30 Days, 6 Months, 12 Months, 24 Months
Secondary	Walking Impairment Questionnaire (WIQ)	Walking Capacity Assessment quantified as the change from pre-procedure to time points specified below.The questions characterize patients' self-reported degree of difficulty in walking a defined distance (5, 3, 2, 1, 1/2 city blocks, 50 ft. or around the home) and speed (running/jogging one block, walking one block quickly, walking one block at average speed, or walking one block slowly). These responses are ranked on a scale of 0 to 4, (0=unable to do, 4=no difficulty). Subscale scores are determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. Each score ranges from 0-100 with lower scores indicating lower performance. The overall score is the average of all 3 subscores.	30 Days, 6 Months, 12 Months, 24 Months
Secondary	Vascular Quality of Life Questionnaire (VascuQol)	Quality of Life evaluation quantified as the change from pre-procedure to time points specified below. VascuQol is an instrument in which the participant is asked about their concerns, abilities, and activities. Overall values can range from 6 to 24, with a higher total sum representing better participant health.	30 Days, 6 Months, 12 Months, 24 Months